(Total Views: 601)
Posted On: 11/08/2021 1:50:48 PM
Post# of 154720
Figgs,
It certainly seems that the phase 2 LH trial, in conjunction the work of many others, demonstrates continued innate immune activation. There are also appears to be a coincidental reactivation of EBV, which can result from and induce innate immune dysfunction.
Dr. Recknor has addressed some of this, though obviously guarding the details, during some of the conference calls.
The pressing question for me is whether they have found a way to separate the LH manifestations. For example, chest pain and dyspnea are more likely to be residual pulmonary injury than the neuro symptoms (as in CFS/ME) of brain fog and fatigue, which are more likely to be addressable by leronlimab.
I'm sure the pathology is better understood, but demonstrating sufficient efficacy will need to be proven.
It certainly seems that the phase 2 LH trial, in conjunction the work of many others, demonstrates continued innate immune activation. There are also appears to be a coincidental reactivation of EBV, which can result from and induce innate immune dysfunction.
Dr. Recknor has addressed some of this, though obviously guarding the details, during some of the conference calls.
The pressing question for me is whether they have found a way to separate the LH manifestations. For example, chest pain and dyspnea are more likely to be residual pulmonary injury than the neuro symptoms (as in CFS/ME) of brain fog and fatigue, which are more likely to be addressable by leronlimab.
I'm sure the pathology is better understood, but demonstrating sufficient efficacy will need to be proven.
(7)
(0)
